+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06174987

Master Rollover Study for Continued Access and Long-Term Safety Assessment of Study Drugs in Advanced and Metastatic Cancer

Led by Daiichi Sankyo · Updated on 2026-10-26

75

Participants Needed

34

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to provide continued treatment and evaluate the long-term safety of various study drugs for participants with advanced or metastatic cancer who have benefited from previous Daiichi Sankyo or Daiichi SankyoAstraZeneca-sponsored studies. It is an open-label, multicenter, phase 3 rollover study designed to offer ongoing access to these therapies and closely monitor participants health. Participants who choose to continue treatment with the drug T-DXd will maintain their last administered dose from the parent study unless a dose reduction is needed due to adverse events. The drug is given as an intravenous infusion every 21 days. Participants previously on comparator treatments may access T-DXd through standard care or other options. The study includes multiple sub-protocols covering different study drugs under a master rollover protocol. During the study, participants will be regularly monitored for adverse events, including serious and special interest events, from baseline until disease progression, loss of benefit, death, pregnancy, withdrawal, commercial access, physician decision, or study closure, up to about 2 years and 9 months. Safety assessments and adherence to contraception or reproductive guidelines will be required. The study spans from early 2024 through early 2028, with ongoing evaluations of treatment impact and participant health throughout.

CONDITIONS

Brief Title

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Research Team

D

Daiichi Sankyo Contact for Clinical Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here